Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CELLCEPT

« Back to Dashboard
Cellcept is a drug marketed by Roche Palo and is included in four NDAs. It is available from four suppliers. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in twenty-eight countries.

The generic ingredient in CELLCEPT is mycophenolate mofetil hydrochloride. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. There is one tentative approval for this compound. Additional details are available on the mycophenolate mofetil hydrochloride profile page.

Summary for Tradename: CELLCEPT

Suppliers / Packagers: see list15

Pharmacology for Tradename: CELLCEPT

Clinical Trials for: CELLCEPT

A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .
Status: Terminated Condition: Interstitial Cystitis; Painful Bladder Syndrome

Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients
Status: Terminated Condition: Stable Renal Transplant Recipients

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
Status: Completed Condition: Systemic Lupus Erythematosus; Arthritis

Study of Gastrointestinal Side Effects in African American Kidney Transplant Recipients Treated With CellCept or Myfortic
Status: Terminated Condition: Kidney Transplantation

Influence of Pantoprazole to the Bioavailability of Myfortic® and CellCept®
Status: Recruiting Condition: Immunosuppressive Medication After Renal Transplantation; Concomitant Medication After Renal Transplantation

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
Status: Not yet recruiting Condition: Interstitial Lung Disease; ILD; Systemic Sclerosis; Scleroderma

Myfortic vs. Cellcept in Kidney Transplant Recipients
Status: Completed Condition: End Stage Renal Disease

A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects
Status: Completed Condition: Healthy Subjects; Pharmacokinetics of Isavuconazole; Pharmacokinetics of Plasma Mycophenolic Acid (MPA); Pharmacokinetics of Plasma Phenolic Glucuronide of MPA (MPAG)

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
Status: Completed Condition: Autoimmune Disease

Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients
Status: Terminated Condition: Kidney Transplantation; Cardiovascular Diseases

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche Palo
mycophenolate mofetil
CAPSULE;ORAL050722-001May 3, 1995RXYes<disabled><disabled>
Roche Palo
mycophenolate mofetil
TABLET;ORAL050723-001Jun 19, 1997RXYes<disabled><disabled>
Roche Palo
mycophenolate mofetil hydrochloride
INJECTABLE;INJECTION050758-001Aug 12, 1998RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CELLCEPT

Drugname Dosage Strength RLD Submissiondate
mycophenolic mofetilFor Oral Suspension200 mg/mLCellcept3/25/2011

International Patent Family for Tradename: CELLCEPT

Country Document Number Publication Date
Hong Kong1012583Dec 02, 2005
Latvia11428Aug 20, 1996
Japan3844491Nov 15, 2006
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn